Dividends

AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for October 14, 2021

AbbVie Inc. (ABBV) will begin trading ex-dividend on October 14, 2021. A cash dividend payment of $1.3 per share is scheduled to be paid on November 15, 2021. Shareholders who purchased ABBV prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABBV has paid the same dividend. At the current stock price of $108.57, the dividend yield is 4.79%.

The previous trading day's last sale of ABBV was $108.57, representing a -10.66% decrease from the 52 week high of $121.53 and a 37.24% increase over the 52 week low of $79.11.

ABBV is a part of the Health Care sector, which includes companies such as McKesson Corporation (MCK) and AmerisourceBergen Corporation (Holding Co) (ABC). ABBV's current earnings per share, an indicator of a company's profitability, is $3.71. Zacks Investment Research reports ABBV's forecasted earnings growth in 2021 as 19.79%, compared to an industry average of 3.6%.

For more information on the declaration, record and payment dates, visit the abbv Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.

Interested in gaining exposure to ABBV through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABBV as a top-10 holding:

  • First Trust Nasdaq Pharmaceuticals ETF (FTXH)
  • First Trust Morningstar ETF (FDL)
  • Invesco Dynamic Pharmaceuticals ETF (PJP)
  • iShares Evolved U.S. Innovative Healthcare ETF (IEIH)
  • WisdomTree U.S. High Dividend Fund (DHS).

The top-performing ETF of this group is IEIH with an increase of 2.26% over the last 100 days. FTXH has the highest percent weighting of ABBV at 7.32%.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ABBV

NASDAQ.com

Nasdaq

Get the latest stock market news, stock information & quotes, data analysis reports, as well as a general overview of the market landscape from Nasdaq.

Read Nasdaq.com's Bio